ArticleCancer management and research2026
Incidence and Risk Factors of Chemotherapy-Induced Hepatotoxicity: A Cross-Sectional Study.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is a major global health concern, causing significant morbidity and mortality, with particularly a high burden observed in low- and middle-income countries (LMICs). While chemotherapy remains a cornerstone of cancer treatment, it often causes adverse effects, particularly hepatotoxicity. Chemotherapy-induced hepatotoxicity (CIH) can severely compromise treatment effectiveness, often leading to necessary dose reductions or discontinuation, thereby increasing patient morbidity and mortality. Despite its clinical significance, there is currently limited data available on the incidence, severity, and risk factors of chemotherapy-induced hepatotoxicity specifically within Uganda or LMIC. Objective: This study aimed to determine the incidence, severity, and risk factors with chemotherapy-induced hepatotoxicity among adult patients with cancer at the cancer unit of Mbarara Regional Referral Hospital (MRRH). Methods: A cross-sectional study was conducted among adult cancer patients receiving chemotherapy at MRRH. Data was collected through patient interviews, chart reviews, and laboratory assessments, including liver enzyme measurements. Statistical analysis was performed using STATA version 17 software. Results: Out of 216 adult patients with cancer. A total of 63 (29.2%) developed chemotherapy-induced hepatotoxicity. Most cases were of grade 1 (n = 51, 81%) followed by grade 2 (n = 8, 12.7%), then grade 3 (n = 4, 6.3%). Risk factors of chemotherapy-induced hepatotoxicity included; living with HIV (adjusted odds ratio (AOR) = 2.5, 95% CI: 1.1-5.6, p-value = 0.033) and diabetes mellitus (AOR = 20.2, 95% CI: 1.7-228.5, p-value = 0.015). Conclusion: Chemotherapy-induced hepatotoxicity affects about one in three cancer patients at MRRH, with HIV and diabetes significantly increasing risk. Routine liver function monitoring and individualized protocols, including prophylactic hepatoprotectants for high- risk patients, are essential to prevent severe hepatotoxicity and improve cancer treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.